Amgen, Cytokinetics' heart drug misses goal in Phase II study
An experimental heart failure treatment developed by Amgen and Cytokinetics didn't meet its goal in a more than 600-patient Phase II study.
An experimental heart failure treatment developed by Amgen and Cytokinetics didn't meet its goal in a more than 600-patient Phase II study.